Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.88% | -18.29% | 0.00% | -18.80% | 45.55% |
| Total Depreciation and Amortization | 0.00% | 15.38% | 0.00% | -7.14% | 600.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.40% | 81.26% | 0.00% | -19.92% | -89.58% |
| Change in Net Operating Assets | -545.93% | -1,226.43% | 0.00% | -104.76% | 288.48% |
| Cash from Operations | -74.36% | -25.29% | 0.00% | -71.07% | 23.70% |
| Capital Expenditure | -400.00% | 30.43% | 0.00% | 97.36% | -190.67% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 0.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -400.00% | -141.03% | 0.00% | 104.47% | -190.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 45,372.26% | 0.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 388.98% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 300.00% | 0.00% | -- | -- |
| Cash from Financing | -100.29% | 76,624.45% | 0.00% | -99.78% | 387.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -109.80% | 2,484.07% | 0.00% | -107.14% | 537.34% |